Get Premium to unlock powerful stock data
MEX:SOBI (Sweden)  
Swedish Orphan Biovitrum AB logo

Swedish Orphan Biovitrum AB

MXN 567.34 (0%) Jul 4
On watch
P/E:
26.32
P/B:
2.78
Market Cap:
MXN 129.73B ($ 6.36B)
Enterprise V:
MXN 146.87B ($ 7.20B)
Volume:
-
Avg Vol (2M):
-
Also Trade In:
Volume:
-
Market Cap MXN:
129.73B
Market Cap $:
6.36B
PE Ratio:
26.32
Avg Vol (2-Month):
-
Enterprise Value MXN:
146.87B
Enterprise Value $:
7.20B
PB Ratio:
2.78
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. In 2019, Sobi acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition). In 2020, new collaborations brought rights to gout drug pegadricase and complement-mediated disease drug Aspaveli.
Name Current Vs Industry Vs History
Cash-To-Debt 0.11
Equity-to-Asset 0.49
Debt-to-Equity 0.41
Debt-to-EBITDA 1.73
Interest Coverage 10.44
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.15
Distress
Grey
Safe
Beneish M-Score -2.59
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
14-Day RSI 100
12-1 Month Momentum % 64.69

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.03
Quick Ratio 0.66
Cash Ratio 0.12
Days Inventory 279.8
Days Sales Outstanding 69.31
Days Payable 46.53

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -3

Financials (Next Earnings Date:2022-07-19)

MEX:SOBI's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil MXN) 38,231.97
EPS (TTM) (MXN) 19.388
Beta 0
Volatility % 64.69
14-Day RSI 100
14-Day ATR (MXN) 0.000007
20-Day SMA (MXN) 567.34
12-1 Month Momentum % 64.69
52-Week Range (MXN) 344.5 - 567.34
Shares Outstanding (Mil) 295.16

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Swedish Orphan Biovitrum AB Filings

Document Form Filing Date
No Filing Data